denosumab
Denosumab is a RANKL inhibitor from Amgen. As Prolia it strengthens bones in osteoporosis; under oncology brands it prevents skeletal complications of cancer that has spread to bone. It works by slowing the cells that break bone down.
This page is based on FDA prescribing information and the EMA medicine record for denosumab, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Bone is constantly renovated by two crews - builders and demolition workers called osteoclasts. RANKL is the work order that keeps the demolition crew oversized and overactive. Denosumab intercepts those work orders, the demolition crew shrinks, and the builders can finally catch up, leaving the structure denser and stronger.
In simple terms
Bones stay healthy through a balance between new bone being made and old bone being broken down by cells called osteoclasts. RANKL is the signal that tells osteoclasts to form and keep working. Denosumab is an antibody that binds RANKL and neutralises it, so fewer osteoclasts form and bone breakdown slows. In osteoporosis this reduces fracture risk; in cancer it protects bones weakened by tumours.
In depth
Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL with high affinity, preventing it from engaging RANK on osteoclast precursors and mature osteoclasts. This inhibits osteoclast formation, function and survival, decreasing bone resorption and increasing bone mineral density. In oncology settings the same blockade reduces osteolysis driven by tumour-derived factors, lowering pathological fractures and other skeletal-related events.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How RANKL inhibitors protect bone
- Bone-building cells release a signal called RANKL that wakes up bone-eating osteoclasts.
- The antibody binds RANKL (membrane-bound or soluble) with high specificity and affinity, before it can activate RANK.
- With RANKL blocked, fewer osteoclasts form and existing ones quiet down.
- Bone loss slows and bone density is better preserved.
Target: RANK ligand (RANKL)
A signalling protein that activates osteoclasts, the cells that dissolve bone; too much RANKL activity tips the balance toward bone loss and weakens the skeleton.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
Approved uses in European Union
EMA- Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
- Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
Official sources
The statements on this page trace back to these records.
- Prolia (denosumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: denosumab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: denosumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.